Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07340697 · ClinicalTrials.gov registry record · Phase 1
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
A Phase 1 study of Actinic Keratosis (AK), sponsored by Rubedo Life Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT07340697 is a Phase 1 study of Actinic Keratosis (AK) that is actively recruiting participants, run by Rubedo Life Sciences. The registered enrollment target is 24 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07340697, a Phase 1 study of Actinic Keratosis (AK), is actively recruiting participants, sponsored by Rubedo Life Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatment with RLS-1496 cream is to clear or decrease the number of AK in the treated area, per lesion counts performed by the Investigator. The main questions it aims to answer are: * Is it safe to apply topical RLS-1496 cream to treat AK once daily for 28 days? * Does topical RLS-1496 lower the number of AKs or eliminate AKs in a treated area when applied once daily for 28 days? Researchers will compare results on the left (treated with RLS-1496) and right (no treatment) forearm. Participants will apply RLS-1496 to an identified area on the left forearm once each day for 28 days and have intermittent clinic visits to examine the arms and have the AK lesions counted until 28 days after the last application of RLS-1496. Participants will also have small skin biopsies on the arms.
Conditions Studied
Interventions
- DRUG RLS-1496 1.0% cream
Study Locations (4)
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Minnesota
- Minnesota Clinical Study Center - New Brighton
Nebraska
- Schlessinger MD Skin Research Center - Omaha
Texas
- Austin Institute for Clinical Research - Pflugerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07340697
The ClinicalTrials.gov registry entry for NCT07340697 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rubedo Life Sciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Actinic Keratosis (AK) appearing as the primary indexed condition, and to 1 intervention - of which RLS-1496 1.0% cream is the first listed.
NCT07340697 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arkansas, Minnesota, Nebraska.
Frequently Asked Questions
What is clinical trial NCT07340697 about?
NCT07340697 is a clinical study titled "Evaluate RLS-1496 Topical Cream for Actinic Keratosis". This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatmen...
What is the current status of trial NCT07340697?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-01. Estimated completion is 2026-05.
What conditions does trial NCT07340697 study?
This clinical trial studies the following conditions: Actinic Keratosis (AK).
What interventions are being tested in trial NCT07340697?
The interventions under investigation include: RLS-1496 1.0% cream (DRUG).
Who is sponsoring clinical trial NCT07340697?
This trial is sponsored by Rubedo Life Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07340697 being conducted?
This trial has 4 study locations across Arkansas, Minnesota, Nebraska, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis (AK)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.